Navigation Links
HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
Date:11/5/2007

ROCKVILLE, Maryland November 5, 2007 Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced the final results of a Phase 2b clinical trial of the investigational drug, Albuferon (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. This Phase 2b study demonstrated that, with half as many injections as Pegasys (peginterferon alfa 2a), Albuferon was just as effective in achieving sustained virologic response (SVR) an undetectable amount of virus in the blood at 24 weeks following the end of treatment with comparable safety and less impairment of health-related quality of life on treatment. Albuferon is administered every two weeks, while peginterferon alfa-2a requires administration every week.

The final Phase 2b data are being presented this week at the 58 th AASLD Annual Meeting in Boston. In two additional press releases also issued by HGS today, the Company announced the full presentations at AASLD of quality-of-life data from the Phase 2b trial, and results from the Phase 2 trial of Albuferon in combination with ribavirin in patients with chronic hepatitis C who had not responded to previous interferon-based treatment regimens.

The final Phase 2b results suggest that the every-two-week dosing regimen of Albuferon halves the number of injections that are required with peginterferon alfa-2a, while providing at least comparable efficacy, comparable safety and the potential for less impairment of quality of life and daily activity, said Stefan Zeuzem, M.D., Professor of Medicine and Chief, Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany. We are continuing the evaluation of the 900-mcg and 1200-mcg doses of Albuferon in larger populations in Phase 3 trials. We also conclude that monthly dosing of Albuferon deserves further evaluation.

In the open-label, multi-center, active-controlled Phase 2b trial, 458 treatment-naive patients with
'/>"/>

Contact: Jerry Parrott
301-315-2777
Edelman Public Relations
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... Lynn Lester as a 2015-2016 inductee into ... recognized with this prestigious distinction for leadership in business. ... professional women, boasting more than 700,000 members and over ... Lynn Lester with this prestigious award,” said NAPW President ...
(Date:6/1/2015)... 2015 The National Association of ... 2015-2016 inductee into its VIP Woman of the ... distinction for leadership in business. NAPW is the ... boasting more than 700,000 members and over 200 ... Kathy into this exceptional group of professional women,” ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Ticket Down announces ... the NBA Western Conference Finals and now will face the ... will be held at the Oracle Arena in Oakland and ... the 2014-15 National Basketball Association season, the Golden State Warriors ... were a team that learned from their playoff failures from ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Linda Kincaid, age ... had an irregular heartbeat. At first she thought it was ... out it was much more than that. After going to ... Linda admitted she felt afraid about what might happen to ... million Americans are diagnosed with valve disease each year. Valve ...
(Date:6/1/2015)... June 01, 2015 Cambia Health ... today a new, interactive Affordable Care Act (ACA) ... The course, called “Affordable Care Act Expert Series, ... the strategic and consultative insights necessary to effectively ... navigate the impacts of the ACA. , The ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:The National Association of Professional Women Inducts Kathy Everette-Gaines, Community Relations Coordinator, Into its VIP Professional Woman of the Year Circle 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 3Health News:A New Online Resource for Those Living with Heart Valve Disease 2Health News:A New Online Resource for Those Living with Heart Valve Disease 3Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 3
... May 12 ULURU Inc. (Amex: ULU ),today ... 31,2008., For the quarter ended March 31, 2008, ... $0.03 per share, compared to a net,loss of $847,000, ... 2007.,The first quarter 2008 net loss was impacted by ...
... Fish diet to avoid being beaten up, thrown out ... result. , That is the fascinating conclusion of the latest ... of Excellence for Coral Reef Studies and James Cook University, ... team who recently revealed fish use the threat of punishment ...
... FRANKLIN, Mass., May 12 PLC Systems Inc.,(AMEX: ... cardiac and vascular medical,device-based technologies, announced today that ... annual meeting of the European,Association of Percutaneous Cardiovascular ... than 11,000 clinicians and,professionals are expected to attend ...
... Study finds little more than half of patients were checked, ... News) -- The dangers of high blood pressure are well-known, ... pressure screening in doctor,s offices and a low percentage of ... , The Stanford University School of Medicine study, published in ...
... 08:30 a.m. EDT at ... http://www.isispharm.com , CARLSBAD, Calif., ... financial results,for the quarter ended March 31, 2008. The Company finished the ... expense related to stock options, compared to a pro forma NOL,of $18.5 ...
... MARKHAM, ON, May 12 /PRNewswire-FirstCall/ - Innolife Pharma, ... over the previous eight,months regarding the formation of ... in these negotiations where final written terms have ... to the Company,s very first,product acquisition. It should ...
Cached Medicine News:Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 2Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 3Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 4Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 5Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 6Health News:Fish diet to avoid fights 2Health News:PLC Medical Systems to Demonstrate RenalGuard(TM) at EuroPCR 2008 2Health News:PLC Medical Systems to Demonstrate RenalGuard(TM) at EuroPCR 2008 3Health News:PLC Medical Systems to Demonstrate RenalGuard(TM) at EuroPCR 2008 4Health News:High Blood Pressure Still Slipping Past Doctors 2Health News:High Blood Pressure Still Slipping Past Doctors 3Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 2Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 3Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 4Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 5Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 6Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 7Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 8Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 9Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 10Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 11Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 12Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 13Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 14Health News:Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture 2
(Date:6/1/2015)... 1, 2015  Research Solutions, Inc. (OTCQB: RSSS), a pioneer ... (STM) information for life science companies, academic institutions, and ... at the LD Micro Invitational being held on June ... Los Angeles . ... June 3rd at 9:30 a.m. Pacific time, with one-on-one ...
(Date:6/1/2015)... 2015  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today ... as ,nal-IRI, in a Phase 1 investigator-sponsored study at ... Data were presented at the 2015 American Society of ... IL. Results from this study show a ... glioma when given intravenously.  Based in part ...
(Date:6/1/2015)... 2015 About Pressure Relief ... area and improve the quality life of patients who ... play a significant role in inhibiting the growth and ... to turn or rotate an immobile patient by providing ... overlay, and specialty beds. These devices have the ability ...
Breaking Medicine Technology:Research Solutions to Present at the LD Micro Invitational on June 3, 2015 2Research Solutions to Present at the LD Micro Invitational on June 3, 2015 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 4Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 5Global Pressure Relief Devices Market 2015-2019 2Global Pressure Relief Devices Market 2015-2019 3
... MOUNTAIN VIEW, Calif., July 20, 2011 Concentric Medical, ... in ischemic stroke patients, today announced the launch of ... the addition of the V 2.0 Soft and V ... of V Series Merci Retrievers® are now approved and ...
... DALLAS, July 20, 2011 ,   ... reports,on The Outlook for Pharmaceuticals for BRIC, Central & ... as well,as E7 countries in its store ... market cover the outlook for pharmaceuticals in,emerging E7 countries as ...
Cached Medicine Technology:Concentric Medical Launches Full Family of Merci Retrievers® in Japan 2Concentric Medical Launches Full Family of Merci Retrievers® in Japan 3ReportsnReports - The Outlook for Pharmaceuticals (BRIC, Asia, Europe, E7) 2ReportsnReports - The Outlook for Pharmaceuticals (BRIC, Asia, Europe, E7) 3ReportsnReports - The Outlook for Pharmaceuticals (BRIC, Asia, Europe, E7) 4
... (T4) is the primary active hormone synthesized ... gland [1]. T4 is synthesized via a ... by the follicular cells, (ii) iodination of ... to formation of 3-monoiodotyrosine and 3,5-diiodotyrosine (MIT ...
... Triiodothyronine (T3) is produced primarily by 5-monodeioination ... the thyroid gland, T3 production occurs at ... that for T4. Release of T3 from ... ~5-8 micrograms/day as compared to 80-100 micrograms/day ...
... a monomeric protein produced and stored in ... is released from the pituitary into the ... regulatory control of hypothalamic somatostatin (SS) and ... frequency of GH release appears to be ...
... monomeric protein produced and stored in somatotrophs ... released from the pituitary into the bloodstream ... control of hypothalamic somatostatin (SS) and GH-releasing ... of GH release appears to be regulated ...
Medicine Products: